Cumberland Pharmaceuticals (CPIX) Q2 2025 earnings summary

Executive summary

• Achieved 23% year-to-date revenue growth, with $22.6 million in net revenues for the first half of 2025, and a 10% increase in Q2 revenues to $10.8 million compared to the prior year period.

• Net income for the six months ended June 30, 2025 was $0.5 million, a turnaround from a $3.0 million loss in the prior year period.

• Advanced clinical programs, including positive Phase II results for ifetroban in Duchenne muscular dystrophy and ongoing studies in systemic sclerosis and idiopathic pulmonary fibrosis.

• Vibativ received regulatory approval in China, launched in the Middle East, and expanded access through Vizient partnership.

• Sancuso and Vibativ acquisitions added significant assets and ongoing royalties.

Financial highlights

• Q2 2025 net revenues: $10.8 million, up 10% year-over-year; H1 2025 net revenues: $22.6 million, up 23% year-over-year.

• Q2 2025 net loss: $0.7 million; H1 2025 net income: $0.5 million; adjusted H1 2025 earnings: $2.8 million ($0.18 per share).

• Cash and cash equivalents at June 30, 2025: $16.1 million.

• Cash flow from operations was $4.7 million for the first six months.

• Working capital improved to $7.2 million with a current ratio of 1.3.

Outlook and guidance

• Management anticipates continued momentum from approved brands, international partnerships, and clinical development progress.

• Expects to announce top-line results from systemic sclerosis study later this year.

• Ongoing focus on expanding product portfolio and leveraging infrastructure for growth.

• Ongoing Phase II clinical programs for ifetroban in multiple indications, with regulatory submissions underway.